During the third quarter, we refined our mission statement to better capture the spirit of what we endeavor to do each day here at Cumberland Pharmaceuticals. It now reads as follows:

working together to provide unique products that improve the quality of patient care

We took several factors into account in designing this statement. First, we wanted our mission to address the constituencies we serve, which include patients in need of care, healthcare providers, our employees, our shareholders, our partners and our community.

We also wanted it to reflect Cumberland’s culture where teamwork is prized, emphasized and expected in order to achieve our goals. Next, it needed to demonstrate our focus on developing, acquiring and distributing differentiated brands. And finally, it emphasizes that the patient is at the core of everything we do. Our collective efforts are directed at providing better alternatives for poorly met medical needs.

As we reflect on the progress we’ve made in fulfilling this mission during the first three quarters of 2023, we are pleased to share a few exciting updates and growth opportunities:

• We recently announced a new publication in Antimicrobial Agents and Chemotherapy detailing the results of the first pediatric study investigating the safety and pharmacokinetics of Vibativ^Æ, our potent injectable antibiotic. The results of the study suggest that a single dose of Vibativ can be safely administered to children 2 to 17 years of age to fight certain serious skin and lung infections.
• We’re also working with our partners in their efforts to register and launch Vibativ in several international markets, which should provide significant catalysts for the product’s future growth.
• We have completed the expansion of our oncology sales division as we work to deliver our newest brand – Sancuso^Æ – to cancer patients, helping them tolerate their chemotherapy treatment.
• Kristalose^Æ, our largest-selling brand, is benefiting from its listing on the New York Medicaid formulary, as well as the ongoing support from our two co-promotion partners.
• Our Vaprisol^Æ product is set to return to the market as we expect an interim supply of compounded product in the next few months.
• As a reminder, we also recently announced the publication of positive results from a clinical study investigating the safety and pharmacokinetics of our Caldolor^Æ product in newborns – supporting the brand’s FDA approval in infants 3 to 6 months of age. Caldolor is the only non-opioid injectable product approved to treat pain and fever in infants, and we are thrilled to further expand its labeling for those youngest of patients.

With Vibativ’s pediatric profile and growing international presence, Sancuso’s integration, Kristalose’s favorable new Medicaid coverage, Vaprisol’s pending contribution, and Caldolor’s new presentation and indication to promote, we are very optimistic about the company’s future prospects. As we move through the final quarter of 2023, we remain focused on our mission and look forward to sharing additional accomplishments in the coming months.